C Diff Treatment

Clostridioides difficile infection (CDI) represents a significant cause of morbidity and mortality, mainly in older and frail subjects. Early identification of outcome predictors, starting from emergency department (ED) admission, could help to improve their management. In a retrospective sin …

Clostridioides difficile commonly causes colitis and extraintestinal Clostridioides difficile infection is a rare finding.Extraintestinal Clostridioides difficile infection occurs due to translocation of flora in the setting of acute inflammation.Extraintestinal Clostridioide …

Clostridioides difficile Treatment Protocol and Healthcare Burden

The plasmid pCD-METRO confers metronidazole resistance in Clostridioides difficile. We showed high sequence similarity among pCD-METRO plasmids from different isolates and identified pCD-METRO and associated metronidazole-resistant isolates in clinical and veterinary reservoirs in the Americas. We r …

The Clostridioides difficile Infection (CDI) treatment guidelines were published in 2021; however, the incorporation of these recommendations into clinical practice was rather irregular and inconsistent. The differences in the implementation of these new guidelines were due, in part, to the variety …

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).

Webinar Series on Clostridioides difficile (C.difficile) Clostridioides (previously known as Clostridium) difficile (C. difficile) is a key cause of healthcare-associated infections and poses a substantial public health threat that carries high morbidity and mortality rates, especially amongst affected elderly patients (more than 65 years). C. difficile infection (CDI) also places a considerable burden on healthcare systems worldwide, with up to one-third of patients who develop an initial episode of CDI subsequently going on to develop a recurrence. While there is widespread scientific literature regarding CDI, there is still a need to better inform the wider medical community on the importance of recognising the microbiome-mediated nature of CDI and how different treatment modalities available can help to resolve the condition and/or restore the gut microbiota to avoid recurrence. In a series of 7 webinar ESNM and GMFH develop a full picture of the C. difficile infection (CDI) reaching from the importance of a healthy gut microbiota, to its detection and testing methods to current and future therapeutic approaches. The course is held by a distinguished Faculty with expertise in the fields of neurogastroenterology, functional gastrointestinal disorders and microbiota. ESNM aim is to promote the dissemination of information and stimulate interesting live discussions that would ultimately improve the healthcare of our patients.

Fidaxomicin is not associated with a shorter length of hospitalization or reduced admission rates among patients with Clostridioides difficile infection compared with vancomycin.

There is a significant need for C difficile treatments that don’t destroy the microbiome.

The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments.

Shrewsbury Town's impressive winning run at the Meadow came to an end when they lost 1-0 at the hands of Charlton Athletic.

There is a significant need for C difficile treatments that don’t destroy the microbiome.

Vancomycin use increased and metronidazole use decreased after the 2017 guideline update. Fidaxomicin use increased but remained low. Improved outcomes associated with fidaxomicin relative to vancomycin suggest benefits from its greater use in Medicare patients.

The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments.

Phase 3 study results show the highly specific antibiotic was safe and effective and particularly effective in patients not taking another antibiotic.

A Health-Related Quality of Life questionnaire designed to gather data on an investigational microbiota therapeutic demonstrated patients felt better about their conditions.

Powder formulations associated with highest risk of infection

#IP2022conf: @FfitzP talks about #Cdiff sharing the experience in Ireland. Reductions in recurrence seen with first line use of fidaxomicin. I’m increasingly convinced that we need to move to this. pic.twitter.com/3YrAQjs8HT— Craig Bradley RN (@CraigBradleyRN) October 17, 2022

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).

Inpatients who develop CDI with comorbid PTSD are at increased risk for sepsis and inpatient mortality. These findings may be due to the impact of PTSD's dysregulation of the hypothalamic-pituitary axis leading to low cortisol production, increased serum cytokine concentrations, and/or increased int …

In 2021, the European and American Infectious Diseases Societies published new guidelines for the treatment of Clostridiodes difficile colitis. They have opted for a change in practice with fidaxomicin being recommended as the first line of treatment, and vancomycin as a second choice. Metronidazole …

Looking back at previous guidelines, Prof. Iqbal provides contextual data regarding the effectiveness of antibiotics and fecal microbiota transplants for C. difficile severe infection @esnm_eu #GMFHCoverage pic.twitter.com/GDVVdLC6nm— GutMicrobiota Health (@GMFHx) October 12, 2022

Dr. Johnson ends his talk by sharing some ongoing research projects to mitigate and prevent C. difficile recurrences @esnm_eu #GMFHCoverage pic.twitter.com/9P5pHztWuL— GutMicrobiota Health (@GMFHx) October 12, 2022

Johnson: Lots of unanswered questions exist regarding the use of anti C. difficile infection antibiotics for prophylaxis. For instance, too high doses disrupt the microbiome boosting the risk of C. difficile infection @esnm_eu #GMFHCoverage pic.twitter.com/uO45G6rabk— GutMicrobiota Health (@GMFHx) October 12, 2022

When it comes to prevention strategies for C. difficile infection recurrence, Dr. Johnson acknowledges that probiotics, discontinuation of proton pump inhibitors and prophylactic-CDI options are not recommended @esnm_eu #GMFHCoverage pic.twitter.com/tbzMnFoB0e— GutMicrobiota Health (@GMFHx) October 12, 2022

Johnson: Fidaxomicin is recommended in various guidelines as an initial C. difficile infection treatment, while fecal transplants and standard of care plus Bexlotoxumab are not recommended in the initial episode @esnm_eu #GMFHCoverage pic.twitter.com/jsvghDkfk5— GutMicrobiota Health (@GMFHx) October 12, 2022

Recent interesting data presented now by Dr. Johnson suggest it is cost-effective adding Bexlotoxumab to CDI antibiotics alone for reducing recurrence @esnm_eu #GMFHCoverage pic.twitter.com/3UV6hy82Bw— GutMicrobiota Health (@GMFHx) October 12, 2022